Observational study / 2009
Higher intake of the soy isoflavone daidzein was linked to reduced breast cancer recurrence in postmenopausal women taking tamoxifen.
Researchers prospectively followed 1,954 female breast cancer survivors for 6.31 years, ascertaining 282 recurrences, to evaluate soy isoflavone intake assessed via food frequency questionnaires an average of 23 months post-diagnosis. Suggestive trends for reduced recurrence risk were seen with increasing quintiles of daidzein and glycetin intake among postmenopausal women (P for trend = 0.08 and 0.06, respectively) and tamoxifen users (P for trend = 0.10 and 0.05, respectively). Among postmenopausal women treated with tamoxifen, those in the highest versus lowest daidzein intake (>1,453 vs. <7.7 microg/day) had a reduced risk of breast cancer recurrence (HR 0.48; 95% CI, 0.21-0.79, P = 0.008).
Shows an association, not proof of cause and effect.
- Study type
- Prospective cohort study
- Who was studied
- 1,954 female breast cancer survivors diagnosed during 1997-2000
- What was measured
- Risk of breast cancer recurrence
THE PAPER
Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study.
Guha N, Kwan ML, Quesenberry CP, Weltzien EK, Castillo AL, Caan BJ. Breast Cancer Res Treat, 2009.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.